Generate Biomedicines (GENB), a clinical-stage generative biology firm, said late Thursday it priced its initial public offering of 25 million common shares at $16 each.
IPO underwriters have a 30-day overallotment option to purchase up to 3.75 million additional shares.
The company expects its shares to start trading on the Nasdaq Global Select Market under the ticker symbol GENB Friday, while the IPO is expected to close Monday.